An economic evaluation of sevelamer in patients new to dialysis

Current Medical Research and Opinion
Matthew J TaylorDonald A Molony

Abstract

The overall objective of this study was to estimate the costs and outcomes associated with treatment with sevelamer for hyperphosphataemia compared with calcium-based binders. Using published data on mortality and hospitalisation rates, a Markov model was developed to predict health outcomes and associated costs for the treatment of hyperphosphataemia using either sevelamer or calcium binders in chronic kidney disease patients who had recently started haemodialysis. Patient outcomes were modelled for 5 years, and incremental cost-effective ratios (ICERs) were calculated for sevelamer relative to calcium carbonate and calcium acetate binders. The perspective adopted was that of the UK National Health Service. The total 5-year discounted treatment cost for patients treated with sevelamer is pound 24,216, while for the calcium carbonate group total cost was pound 17,695. This is an incremental cost of pound 6521 per sevelamer-treated patient over 5 years. Patients receiving sevelamer can be expected to experience 2.70 quality-adjusted life years (QALYs) compared to 2.46 for those treated with calcium carbonate (i.e. an incremental gain of 0.24 QALYs). This results in an incremental cost per QALY of pound 27,120 and an incremental ...Continue Reading

References

May 7, 1998·Health Policy·G A de WitF T de Charro
Nov 26, 1999·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·G M ChertowE Slatopolsky
Jan 5, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·G Ardine de WitFrank Th de Charro
Jun 26, 2002·Kidney International·Glenn M ChertowUNKNOWN Treat to Goal Working Group
Dec 13, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hugh C RaynerFriedrich K Port
Jul 31, 2004·Journal of the American Society of Nephrology : JASN·Geoffrey A BlockGlenn M Chertow
Dec 21, 2004·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·E RemákM Zagari
Jun 3, 2005·Current Opinion in Nephrology and Hypertension·Catherine M Shanahan
Sep 24, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Krista F HuybrechtsJudith A O'Brien
Dec 13, 2005·Kidney International. Supplement·Keith A HruskaRichard J Lund
Dec 13, 2005·Kidney International. Supplement·Adeera Levin
Apr 20, 2006·Disease Management : DM·Randolph A ChenAllen R Nissenson
Apr 20, 2006·Disease Management : DM·Micah L ThorpEric S Johnson
Mar 22, 2007·Seminars in Dialysis·Rukshana C Shroff, Catherine M Shanahan
Jun 28, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Braden MannsMarcello Tonelli

❮ Previous
Next ❯

Citations

Dec 20, 2012·Therapeutic Advances in Chronic Disease·Mario CozzolinoMaurizio Gallieni
Jul 18, 2014·Nephro-urology Monthly·Antonio Bellasi, Biagio Raffaele Di Iorio
Sep 4, 2013·Drugs in R&D·Aurélie LengletZiad A Massy
Jul 16, 2014·Kidney International Supplements·Shunsuke GotoShinichi Nishi
Sep 22, 2009·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Hirotaka KomabaMasafumi Fukagawa
Apr 29, 2014·Journal of Pediatric Urology·Jessica C LloydJonathan C Routh
Dec 14, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Haesuk ParkRon Akehurst
Aug 21, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Sankar D NavaneethanGiovanni F M Strippoli
Feb 18, 2011·The Cochrane Database of Systematic Reviews·Sankar D NavaneethanGiovanni Fm Strippoli
Mar 8, 2021·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Kamolpat ChaiyakittisoponAmmarin Thakkinstian

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Braden MannsMarcello Tonelli
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Krista F HuybrechtsJudith A O'Brien
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Alan BrennanVictoria Abbott
Kidney International
J Silver
© 2021 Meta ULC. All rights reserved